Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
about
The EMPA-REG outcome study: critical appraisal and potential clinical implicationsDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.The role of empagliflozin in the management of type 2 diabetes by patient profile.Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study.Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled StudyEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesAn evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.The effect of SGLT2 inhibitors on cardiovascular events and renal function.The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Impact of empagliflozin in patients with diabetes and heart failure.Cardiovascular effects of anti-diabetes drugs.Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossovEarly effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring.Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
P2860
Q26748742-96E63E96-43F4-47D7-B835-082EA62109C6Q26749281-61277867-8EE6-4ECA-87CC-CCE9EB8704F9Q32186373-668999C6-F788-492D-81D6-22B2835EC362Q33619161-EDBF4BB6-3B5A-41FE-89D2-73A161F78AC9Q33890770-4FCC1BD8-BDBD-4B00-8205-08D4E3C846A3Q35592873-FED87B01-2581-4BBC-9006-E10815E53DA7Q36402095-29A41ACF-491B-4875-B866-C49257C1D750Q36469075-5055C157-3E06-443C-A400-D38D4D667267Q37080615-9A5802CE-C813-444E-AB2B-676CDE3E5A78Q37325818-A8481ED1-B339-43FA-A88F-B22D8AB2E8F0Q37586729-BD6438FF-A7F0-4498-A49A-A0362F38B89AQ37661798-1CB908F5-0893-4772-8191-E5984982BD34Q37721942-3F8659E6-BA70-4B97-AAFB-E6C03E986408Q38614488-73FD083F-022E-478C-9E8D-8CCA7F3493B8Q38793748-A1BE66EB-DE1E-421C-8557-C50B844565F5Q38821464-D1FE2574-B583-426F-9823-8DFEF920926AQ38822815-D7F77F73-D8B8-4B89-AC81-D72453082EB9Q38857056-BCE854F3-3F3D-4FD6-AA45-A19E74A932B3Q38978384-585BF3FC-6F7C-495C-ABCE-9A558EF06B5FQ39101008-60FFD2AF-77D8-480B-A0DA-54415C5CA450Q39408236-1E6A5819-35A9-4893-8502-5BAACB7816EAQ41154151-A2EA8BFA-BB99-4B3F-8487-DE3A36522D0EQ41263234-A9332AEF-71D0-4C9E-B827-32B5A0309113Q41849079-B5116080-55B4-4B41-88D3-79CBF816E21CQ47236288-E1F443EC-470B-49E1-A2DB-7897B2CB4E8EQ58709946-A8460AB3-1E50-408A-B0EA-C40F8F03DC0A
P2860
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@ast
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@en
type
label
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@ast
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@en
prefLabel
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@ast
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@en
P2093
P2860
P1476
Effect of empagliflozin monoth ...... cebo-controlled, 4-week study.
@en
P2093
Afshin Salsali
Kazuki Koiwai
Kohei Inoue
Rimei Nishimura
Søren S Lund
Thomas Hach
Uli C Broedl
Yuko Tanaka
P2860
P2888
P356
10.1186/S12933-014-0169-9
P407
P577
2015-01-30T00:00:00Z
P5875
P6179
1040395366